In the French pharmaceutical industry, there were 11 M&A deals announced in Q2 2023, worth a total value of $321.2m, according to GlobalData’s Deals Database. The $301.3m acquisition of adare pharmaceuticals by dsm-firmenich was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in France decreased by 88% in Q2 2023 compared with the previous quarter’s total of $2.6bn and fell by 6% as compared to Q2 2022. Related deal volume increased by 22% in Q2 2023 versus the previous quarter and was 175% higher than in Q2 2022.
The top-ranked legal advisorss supporting these M&A deals in France Q2 2023 were CMS Legal Services EEIG; Kirkland & Ellis; CLARIS Avocats with 2, 2, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.